The future treatment options for patients with high-risk non-muscle invasive bladder cancer that are BCG naive or BCG unresponsive, I think, is very exciting, and we have a lot of really great new therapeutics that are penetrating the market. And most importantly, this is going to help us treat our patients and provide them with more effective treatments. This may be intravesical treatments where you have novel adenoviral vectors and oncolytic adenoviruses, either alone or combined with checkpoint inhibitors. I think the future of BCG unresponsive disease and potentially BCG naive disease is the combination of intravesical agents combined with systemic checkpoint inhibitors.